A role in migration of prostate cancer cell has indeed been confirmed by Zhu et al. (2020) who reported that Ibrutinib significantly inhibited cell proliferation, migration and invasion of prostate cancer cells as well as protein synthesis of MMP-2 and MMP-9. Here, MMP2 is linked to prostate carcinoma.